12:00 AM
May 17, 2010
 |  BC Week In Review  |  Company News  |  Other News

Avexa infectious news

Avexa plans to reduce headcount and pursue strategic alternatives after discontinuing development of HIV candidate apricitabine. Avexa said it was unable to find a partner for the cytidine analog nucleoside reverse transcriptase inhibitor (NRTI),...

Read the full 148 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >